PDGFRB and telomere syndrome: Regorafenib, a TKI targeting VEGFR1-3, RET, KIT, PDGFR and Raf, was found to be associated with a minor PFS advantage in non-adipocytic STS progressing on anthracycline in a single phase II study [54].